in

July / August 2020

In this issue
  • in

    TOP 50 MEDICAL DEVICE COMPANIES

    MEDTECH The medical device sector saw gains from last year. However, that was before Covid-19 hit. We will see the results of that next year. The sector comprises medical device, medical equipment, capital equipment and medical technology companies. The total income this past year across the sector was $428B, up from $413B in 2018. All […] More

    Read More

  • in

    MOTIVIDEOS

        By Cari Kraft, Jacobs Management Group We hope you’re all well, and dealing with this crisis as best you can. On a personal and a business level, this has thrown all of us, and we want to provide whatever help we can. Normally, Motivideos features advice on getting morning meetings off to an […] More

    Read More

  • in

    ROUNDTABLE- SALES IN THE ERA OF COVID-19

    SALES IN THE ERA OF COVID-19 Executives from Incyte, Janssen, Merck, Teva and SK life science Offer Their Views Our Moderator: Our panel of experts: ROUNDTABLE Continuing our coverage of the industry response to the Covid-19 crisis, in this roundtable we focus on its effect on sales forces and how they are adapting to the […] More

    Read More

  • in

    Industry Trends: By the numbers

    Compiled by Cari Kraft, Jacobs Management Group, Inc. Case Fatality Rate For Covid-19 In U.S. As of August 24, over 64,000,000 tests had been conducted in theU.S., and the case fatality rate had dropped to 3.1% from a high of 7.2% on March 4th. However, this is only what we have been able to measure […] More

    Read More

  • in

    Seqirus Exec on Vaccine Differentiation

    Brent MacGregor has been around the world, with some of the top companies in the vaccines industry. He put in 16 years at Sanofi Pasteur, most recently serving as Managing Director in Japan. Following Sanofi Pasteur, he was president of Novartis Vaccines U.S. and then CEO for Influenza Vaccines. At that point, Novartis was involved […] More

    Read More

  • in

    WHY I WORK IN HEALTHCARE

    In this column, we have often featured people who work all over the industry, expressing how much they get out of the results they are able to achieve. Now those people are more vital – to every one of us – than they have ever been. In our last issue we encouraged everyone to show […] More

    Read More

  • in

    The Orphan Drug Outlook

    Orphan drugs are going through an interesting era. Although they are intended to treat rare conditions – orphan diseases that affect less than 200,000 persons in the US – this area has taken on a special importance in recent years. For one thing, the investigation of orphan drugs often leads to medical breakthroughs that might […] More

    Read More

American HealthCare Capital

American Healthcare Capital

The Orphan Drug Outlook